H. Lundbeck, Lundbeck and BioTie sign agreement for nalmefene

H. Lundbeck A/S and Biotie Therapies Corp. have today signed an agreement on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, and South-Korea. Under the terms of the agreement, BioTie has granted Lundbeck an exclusive license to market and distribute nalmefene as a prescription medicine for the treatment of substance abuse disorders and impulse control disorders.